Anti-WNT2 monoclonal antibodies not only restore DC differentiation but also enhance T cell activation, improving the anti-tumor immune response and boosting the efficacy of immune checkpoint inhibitors in tumor models (39). The gene discussed is WNT2; the disease is neoplasm.